Vanda Pharmaceuticals traded at $7.11 this Thursday March 26th, decreasing $0.14 or 1.93 percent since the previous trading session. Looking back, over the last four weeks, Vanda Pharmaceuticals lost 20.20 percent. Over the last 12 months, its price rose by 54.57 percent. Looking ahead, we forecast Vanda Pharmaceuticals to be priced at 7.03 by the end of this quarter and at 6.42 in one year, according to Trading Economics global macro models projections and analysts expectations.
Vanda Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its commercial portfolio consists of two products, HETLIOZ (tasimelteon) for the treatment of jet lag disorder, pediatric non-24, delayed sleep phase disorder (DSPD) and autism spectrum disorder (ASD), and Fanapt (iloperidone) for the treatment of bipolar disorder and Parkinson's disease psychosis (PDP) and a long acting injectable (LAI) formulation for the treatment of schizophrenia. Its other product pipeline includes Tradipitant (VLY-686), VTR-297, VSJ-110 and BPO-27. VLY-686, is for the treatment of gastroparesis, motion sickness, atopic dermatitis and COVID-19 pneumonia. VTR-297, is for the treatment of hematologic malignancies. VSJ-110, is for the treatment of dry eye and ocular inflammation. BPO-27, is for the treatment of secretory diarrhea disorders, including cholera. Its other product includes VQW-765.